Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis

[1]  A. Witney,et al.  Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid , 2023, PLOS global public health.

[2]  C. Köser,et al.  Minimum inhibitory concentrations and sequencing data have to be analysed in more detail to set provisional epidemiological cut-off values for Mycobacterium tuberculosis complex , 2023, European Respiratory Journal.

[3]  J. Turnidge,et al.  The determination of epidemiological cut-off values requires a systematic and joint approach based on quality controlled, non-truncated minimum inhibitory concentration series , 2023, European Respiratory Journal.

[4]  Daniel J. Wilson,et al.  Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis , 2023, The Lancet. Microbe.

[5]  A. Crook,et al.  Treatment Strategy for Rifampin-Susceptible Tuberculosis. , 2023, The New England journal of medicine.

[6]  Z. Iqbal,et al.  Repeated evolution of bedaquiline resistance in Mycobacterium tuberculosis is driven by truncation of mmpR5 , 2022, bioRxiv.

[7]  A. Crook,et al.  Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. , 2022, The New England journal of medicine.

[8]  M. DeJesus,et al.  Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis , 2022, Antimicrobial agents and chemotherapy.

[9]  Z. Iqbal,et al.  A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics , 2022, PLoS biology.

[10]  K. Fielding,et al.  TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis , 2022, Trials.

[11]  A. Van Rie,et al.  Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis , 2021, The Lancet. Microbe.

[12]  L. Freschi,et al.  Role of Epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine Resistance in Mycobacterium tuberculosis Complex , 2021, bioRxiv.

[13]  P. Fowler.  Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis , 2021, European Respiratory Journal.

[14]  B. D. de Jong,et al.  MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era , 2020, Genome medicine.

[15]  J. Sacchettini,et al.  Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis , 2020, Antimicrobial Agents and Chemotherapy.

[16]  F. Balloux,et al.  Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis , 2020, The Lancet. Microbe.

[17]  Y. Pang,et al.  Reduced susceptibility of Mycobacterium tuberculosis to bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  C. Köser,et al.  Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. , 2020, The Journal of antimicrobial chemotherapy.

[19]  M. Matsumoto,et al.  OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor , 2020, Antimicrobial Agents and Chemotherapy.

[20]  J. Parkhill,et al.  Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex , 2020, Genome Medicine.

[21]  F. Balloux,et al.  Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients , 2020, European Respiratory Journal.

[22]  S. Niemann,et al.  Bedaquiline-resistant Tuberculosis: Dark Clouds on the Horizon. , 2020, American journal of respiratory and critical care medicine.

[23]  F. Balloux,et al.  Dynamics of within-host Mycobacterium tuberculosis diversity and heteroresistance during treatment , 2020, EBioMedicine.

[24]  L. Rigouts,et al.  An African origin for Mycobacterium bovis , 2019, bioRxiv.

[25]  S. Niemann,et al.  Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  V. Eldholm,et al.  Lineage specific histories of Mycobacterium tuberculosis dispersal in Africa and Eurasia , 2019, Molecular ecology.

[27]  Jim F Huggett,et al.  Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs , 2019, Genome Medicine.

[28]  I. Mokrousov,et al.  Acquisition of bedaquiline resistance by extensively drug resistant Mycobacterium tuberculosis strain of Central Asian Outbreak clade. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  A. Ghafoor,et al.  Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan , 2019, Antimicrobial Agents and Chemotherapy.

[30]  D. Brites,et al.  The molecular clock of Mycobacterium tuberculosis , 2019, bioRxiv.

[31]  R. Peters,et al.  Clofazimine Exposure In Vitro Selects Efflux Pump Mutants and Bedaquiline Resistance , 2019, Antimicrobial Agents and Chemotherapy.

[32]  Phelim Bradley,et al.  Ultra-fast search of all deposited bacterial and viral genomic data , 2019, Nature Biotechnology.

[33]  A. Fateh,et al.  High Prevalence of Bedaquiline Resistance in Treatment-Naive Tuberculosis Patients and Verapamil Effectiveness , 2019, Antimicrobial Agents and Chemotherapy.

[34]  Sebastián Duchêne,et al.  BEAST 2.5: An advanced software platform for Bayesian evolutionary analysis , 2018, bioRxiv.

[35]  Nalini Singh,et al.  High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen , 2018, European Respiratory Journal.

[36]  F. Balloux,et al.  Whole genome sequencing Mycobacterium tuberculosis directly from sputum identifies more genetic diversity than sequencing from culture , 2018, BMC Genomics.

[37]  Alexey M. Kozlov,et al.  RAxML-NG: a fast, scalable and user-friendly tool for maximum likelihood phylogenetic inference , 2018, bioRxiv.

[38]  T. Clark,et al.  Global expansion of Mycobacterium tuberculosis lineage 4 shaped by colonial migration and local adaptation , 2018, Science Advances.

[39]  R. Peters,et al.  Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis , 2018, Data in brief.

[40]  Sebastian M. Gygli,et al.  Multiple Introductions of the Mycobacterium tuberculosis Lineage 2–Beijing into Africa over centuries , 2018, bioRxiv.

[41]  T. Clark,et al.  Identifying mixed Mycobacterium tuberculosis infections from whole genome sequence data , 2018, BMC Genomics.

[42]  Emmanuel Paradis,et al.  ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R , 2018, Bioinform..

[43]  V. Sintchenko,et al.  Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia. , 2018, Tuberculosis.

[44]  P. Rancoita,et al.  Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis , 2018, Antimicrobial Agents and Chemotherapy.

[45]  Daniel J. Wilson,et al.  Bayesian inference of ancestral dates on bacterial phylogenetic trees , 2018, bioRxiv.

[46]  K. Dheda,et al.  Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa , 2018, European Respiratory Journal.

[47]  Christian Beisel,et al.  Treemmer: a tool to reduce large phylogenetic datasets with minimal loss of diversity , 2018, BMC Bioinformatics.

[48]  C. Fraser,et al.  Convergent evolution and topologically disruptive polymorphisms among multidrug-resistant tuberculosis in Peru , 2017, PloS one.

[49]  O. Antonova,et al.  Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region , 2017, The Journal of antimicrobial chemotherapy.

[50]  Alimuddin Zumla,et al.  Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study , 2017, European Respiratory Journal.

[51]  T. Clark,et al.  Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. , 2017, The Lancet. Respiratory medicine.

[52]  Bin Wang,et al.  Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis , 2017, Antimicrobial Agents and Chemotherapy.

[53]  Y. Yazdanpanah,et al.  Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis , 2017, European Respiratory Journal.

[54]  T. Tønjum,et al.  Tuberculosis Outbreak in an Educational Institution in Norway , 2017, Journal of Clinical Microbiology.

[55]  Thomas Abeel,et al.  Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into emergence and spread of multidrug resistance , 2017, Nature Genetics.

[56]  Guangchuang Yu,et al.  ggtree: an r package for visualization and annotation of phylogenetic trees with their covariates and other associated data , 2017 .

[57]  L. Rigouts,et al.  Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline , 2016, The Journal of antimicrobial chemotherapy.

[58]  F. Balloux,et al.  Antimicrobial Resistance in Mycobacterium tuberculosis: The Odd One Out. , 2016, Trends in microbiology.

[59]  Koen Andries,et al.  Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis , 2016, Antimicrobial Agents and Chemotherapy.

[60]  Simon R. Harris,et al.  SNP-sites: rapid efficient extraction of SNPs from multi-FASTA alignments , 2016, bioRxiv.

[61]  Phelim Bradley,et al.  Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis , 2015, Nature Communications.

[62]  A. Diacon,et al.  Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis , 2015, European Respiratory Journal.

[63]  G. Bloemberg,et al.  Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. , 2015, The New England journal of medicine.

[64]  Carmen Z. Suarez,et al.  Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[65]  Ana Conesa,et al.  Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data , 2015, Bioinform..

[66]  K. Dheda,et al.  Molecular Epidemiological Interpretation of the Epidemic of Extensively Drug-Resistant Tuberculosis in South Africa , 2015, Journal of Clinical Microbiology.

[67]  Thomas Abeel,et al.  Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal , 2015, PLoS medicine.

[68]  Gang Sun,et al.  Southern East Asian origin and coexpansion of Mycobacterium tuberculosis Beijing family with Han Chinese , 2015, Proceedings of the National Academy of Sciences.

[69]  R. Bouckaert,et al.  bModelTest: Bayesian phylogenetic site model averaging and model comparison , 2015, BMC Evolutionary Biology.

[70]  C. Dye,et al.  Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: A Prospective Cohort Study , 2015, PLoS medicine.

[71]  Francesc Coll,et al.  Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences , 2015, Genome Medicine.

[72]  Nalin Rastogi,et al.  The Association between Mycobacterium Tuberculosis Genotype and Drug Resistance in Peru , 2015, PloS one.

[73]  Gemma L. Kay,et al.  Eighteenth-century genomes show that mixed infections were common at time of peak tuberculosis in Europe , 2015, Nature Communications.

[74]  J. Parkhill,et al.  Large-scale whole genome sequencing of M. tuberculosis provides insights into transmission in a high prevalence area , 2015, eLife.

[75]  Nalin Rastogi,et al.  Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage , 2015, Nature Genetics.

[76]  Francesc Coll,et al.  A robust SNP barcode for typing Mycobacterium tuberculosis complex strains , 2014, Nature Communications.

[77]  Eduardo Gotuzzo,et al.  Multidrug-resistant tuberculosis and culture conversion with bedaquiline. , 2014, The New England journal of medicine.

[78]  B. D. de Jong,et al.  Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline , 2014, PloS one.

[79]  S. Cole,et al.  Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis , 2014, Antimicrobial Agents and Chemotherapy.

[80]  Mauricio O. Carneiro,et al.  From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.

[81]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[82]  M. Suchard,et al.  Improving the accuracy of demographic and molecular clock model comparison while accommodating phylogenetic uncertainty. , 2012, Molecular biology and evolution.

[83]  D. Froese,et al.  Antibiotic resistance is ancient , 2011, Nature.

[84]  K. Andries,et al.  Rates and Mechanisms of Resistance Development in Mycobacterium tuberculosis to a Novel Diarylquinoline ATP Synthase Inhibitor , 2009, Antimicrobial Agents and Chemotherapy.

[85]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[86]  THE WORLD HEALTH ORGANIZATION , 1954 .

[87]  Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium , 2022 .

[88]  OUP accepted manuscript , 2022, Journal of Antimicrobial Chemotherapy.